Pioneering Endocannabinoid-Based Drug Discovery
We want to help people living with debilitating conditions by developing non-addictive pain medications to reduce the reliance on opioids.
Our Science
Octavian has a range of compounds in drug development, including proprietary derivatives, in-licensed compounds, and new chemical entities (NCEs) designed to target the Endocannabinoid System (ECS).
Meet the Team
With expertise across pharmaceutical operations, R&D, intellectual property, law, and finance, Octavian’s team has a proven track record of commercial and clinical excellence, with over 20 regulatory approvals for new medicines in the US and the EU. United by a shared commitment, our team is dedicated to delivering breakthrough therapies for debilitating conditions.
Recent News
Follow our journey from early-stage discovery to clinical trials as we develop innovative medicines targeting the Endocannabinoid System (ECS) to help people living with debilitating conditions.
